Targeted Hope Newsletter 

August 2011
Special Learn for Life Edition
In this Issue
From the Chairman
Upcoming Events
From the Program Chairs
2011 Speakers
6th Annual Singin' for Cures Fundraiser
World Stem Cell Awareness Day Campaign
Quick Link

Find us on Facebook    Follow us on Twitter    View our videos on YouTube    Find us on Facebook                                                    



AUGUST 16th at 5:30 PM 

at LIVESTRONG Headquarters 


Roger S. Gammon, M.D., Medical Director of Research & Interventional Cardiologist with Austin Heart,PLLC will discuss the types, sources, and functions of stem cells and review progress gained in using stem cell treatments for vascular disease, heart attacks and limb restoration.
























TSCR Co-Hosts 




Emerson Perin, MD, PhD 

Director, Stem Cell Center
Director, Clinical Research for Cardiovascular Medicine
Texas Heart Institute   





Dear Texans,   


As we like to say here," Texas isn't a state, it's a state of mind". TSCR's state of mind right now is to strive to make Texas one of the world leaders in stem cell research and therapies.  By increasing the number of clinical trials, we'll give hope to our fellow Texans currently suffering from chronic diseases.   

We took another major step in that direction again this week. TSCR is tremendously honored and humbled to welcome James T. Willerson, MD one of the leading stem cell scientists and cardiologists in the world, to our Medical Advisory Committee. Be sure to read about Dr. Willerson in this issue.

Dr. Willerson and three other members of our Medical Advisory Committee: Jay Schneider, MD, PhD of UTSW, Sean Savitz, UTHSC Houston, and Darwin Prockop, Texas A&M Institute for Regenerative Medicine, were invited to participate in the Texas Medical Board Stem Cell Research Stakeholder Workgroup discussing new rules regarding adult stem cell research and treatments. We are encouraged and pleased that recognized experts are representing major research institutions during the discussions. 

We are less than two weeks away from our next event to be held at LIVESTRONG Headquarters. Please make sure you have August 16th from 5:30-8:00PM on your calendar. It's another don't miss event. Momentum has been building and there may be a surprise guest or two--you never know.

Most of you have the September 30th symposium already circled as well. The speakers are truly amazing and this issue features background on all 14 of our 2011 speakers.   

We still have tables available for our Annual Fundraiser on September 30th. You will not want to miss the inspirational messages from Dr. Wise Young, Roman and Don Reed.  Be sure to read about these three great leaders below. They are well recognized around the world for their continued contributions to spinal cord research and unwavering advocacy for research to benefit patients suffering from spinal cord injury and disease. When our loved ones in wheel chairs are able to walk again, you will recall their inspiring words--they are true catalyst to finding a cure.

We can't wait to see everyone on Tuesday, August 16th!



David L. Bales




Stem cell science is an interdisciplinary field that often requires collaboration from researchers at multiple universities.     



As part of TSCR's ongoing public outreach and education initiative, 

this event is free and open to the public.


SOURCE: Flickr/Pacific Northwest Regional Laboratory


Our August Special Edition issue of Targeted Hope is dedicated to the 2011 Learn for Life educational events.  To catch up on last month's daily news, be sure visit us on Twitter .  Here are a few headlines:


July 8         Tissue Genesis Joins with NASA & DoD for the Last Space Shuttle Launch, STS-135

July 27       A Victory for Stem Cell Research and Patients

July 27       Judge sides with Obama administration, tosses suit over federal funding of stem cell research

July 28       Misguided Stem Cell Legal Battle Comes to an End
August 2   Court quashes stem-cell lawsuit

August 3   NIH appoints Director of Intramural Center for Regenerative Medicine   

August 4   Perry, Allies Lay Groundwork for TX Stem Cell Industry 

August 4   Stanford legal expert discusses future of stem cell research on ScienceLive  

August 4   Rick Perry Has Stem Cell Procedure, Then Works to Bring it to Texas        

The Texans for Stem Cell Research 2nd Annual Symposium will showcase eminent researchers and physicians currently investigating potential stem cell applications for treating diseases such as Alzheimer's, Parkinson's, multiple sclerosis (MS), heart disease, diabetes, degenerative eye diseases, spinal cord injury, stroke, and traumatic brain injury.  Our distinguished panel of speakers includes leaders from all corners of the US and around the world.  They are well recognized and represent diverse specialties, including: cardiology, endocrinology, neurology, immunology and oncology. This symposium will highlight the most current developments in the emerging field of regenerative medicine. Respected industry leaders will also cover new technologies and directions in cord blood and stem cell banking.  TSCR is confident the symposium will expand the understanding and support for safe, ethical and responsible stem cell research.  


We have dedicated this issue of Targeted Hope to introducing the 2011 distinguished panel of guest speakers.  They will travel to our great capital city on September 30th to speak to all interested Texans and we encourage you to RSVP today to reserve your seat.   

We also wish to thank the Ranch Road Team for their excellent work on the Learn for Life Series and Symposium invitaitons, Wyatt McSpadden Photography, UTSW Olson Lab for the scientific images, Buck Ramsey's Grass, 2005, Texas Tech University Press and Beth McConnell at 10 Miles West.  





Keri Kimler  & Megan Combs

Program Chairs, 2nd Annual Stem Cell Research Symposium 2011



We are proud to announce Austin Heart, PLLC will return this year to moderate the 2011 Annual Learn for Life Stem Cell Research Symposium.  Roger S. Gammon, M.D. is the Medical Director of Research & Interventional Cardiologist with Austin Heart has been the principal investigator of more than 50 trials and sub-investigator of 20 clinical trials.  His stem cell research is focused on adult stem cell applications in patients after Acute Myocardial Infarction (MI) and in patients with Critical Limb Ischemia (CLI) due to Peripheral Vascular Disease.  The results from a Phase I trial were published in the Journal of the American College of Cardiology and reported that patients were treated safely with intravenous adult human mesenchymal stem after a heart attack.  In addition, these patients had fewer arrhythmias, improved heart and lung function, and improvement in overall condition.  He is a principal investigator conducting the Phase II, Multi-center study evaluating the safety and efficacy of adult human mesenchymal stem cells for acute myocardial infarction.  Austin Heart is currently participating in a trial using the patient's own stem cells to potentially save their leg from amputation when interventions and surgery are not possible. There is currently no other treatment option for these patients. Dr. Gammon will be speaking at our August Learn for Life event at Livestrong Headquarters.  

Darwin Prockop, MD, PhD is a Professor of Molecular and Cellular Medicine and the Stearman Chair in Genomic Medicine.  He is also the Director of the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White in Temple, Texas and a pioneer in the areas of human bone marrow-derived stem cells and their biology and clinical applications. Dr. Prockop has authored or co-authored more than 500 publications, is a frequent speaker at distinguished international events pertaining to matrix biology and stem cell science, and has been awarded three honorary degrees. Amongst his many accomplishments are appointments to both the National Academy of Sciences and the National Institute of Medicine. The Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine (IRM) at Scott & White Hospital was established in August 2008 as joint venture between the Texas A&M Health Science Center College of Medicine, Scott & White, and the Temple Bioscience District. The institute is studying adult stem/progenitor cells from bone marrow referred to as mesenchymal stem cells, multipotent stromal cells or MSCs. The laboratory is engaged in defining the cells with a variety of techniques that include immunocytochemistry, microarrays of transcripts, and proteomics.  The cells are being studied in a variety of models for human disease that include heart disease, lung diseases, diabetes, stroke, and head trauma.  In addition, plans are being developed to use the cells in clinical trials in patients.  


The goal of the IRM is to bridge the gap between basic science and clinical translation in the field of regenerative medicine and experimental cell therapeutics. Through active collaboration between basic scientists and clinicians in Central Texas, the IRM hopes to tackle the ambitious task of discovering novel therapies for intractable diseases to relieve human suffering.

James T. Willerson, MD is the President and Medical Director, Director of Cardiology Research, Co-Director of the Cullen Cardiovascular Research Laboratories at the Texas Heart Institute (THI) and is immediate past President of The University of Texas Health Science Center in Houston (UTHSCH). Dr. Willerson holds the Edward Randall III Professor of Internal Medicine at The UT Medical School at Houston, the Dunn Chair in Cardiology Research at THI, the Willerson/O'Quinn Chair at THI, the "James T. Willerson, MD Distinguished Chair in Cardiovascular Diseases" at The UTSW Medical School in Dallas, and has a swimming scholarship named for him at UT Austin. Dr. Willerson is a Phi Beta Kappa graduate of UT Austin, was a four-year swimming letterman, a member of the Texas Cowboys of UT Austin, an AOA graduate of the Baylor College of Medicine, and he received his post graduate training at Harvard Medical School (HMS) and the Massachusetts General Hospital (MGH) in Boston. Dr. Willerson is a member of the Institute of Medicine of the National Academy of Science.  As the longest-serving Editor-in-Chief of Circulation, journal of the AHA, his tenure lasted 11 years.  In addition to having served on numerous editorial boards for professional publications, he has edited or co-edited twenty-four textbooks, including his signature textbook, the Third Edition of Cardiovascular Medicine, released in February of 2007, and he has published over 920 scientific articles. The James T. Willerson Distinguished Chair in Cardiology was named in his honor at the Institute of Molecular Medicine for the Prevention of Human Disease at The University of Texas Health Science Center at Houston, 2009.  In June of 2009, he was elected to The University of Texas Hall of Honor for accomplishments in varsity swimming from 1957-1961 and for ongoing professional contributions in the field of medicine.  In 2009, he received the Ray C. Fish Award from Texas Heart Institute for "An individual whose endeavors have made significant contributions to cardiovascular medicine or surgery.  Dr. Willerson's research concentrates on the detection and treatment of unstable atherosclerotic plaques, and the discovery of the genes and abnormal proteins responsible for cardiovascular disease.


Dr. Willerson and colleagues, Dr. Emerson Perin and Ed T.H. Yeh, have been directly involved in seminal research in the use of stem cells for the repair of hearts and cardiovascular vessels injured by heart attacks and heart failure, and they are responsible for major discoveries, landmark publications, and for Texas Heart Institute's being awarded the first FDA-approved clinical trial in the use of stem cells. 

Eric N. Olson, PhD  is Professor And Chairman, Department of Molecular Biology, Annie and Willie Nelson Professorship in Stem Cell Research, and Pogue Distinguished Chair in Research on Cardiac Birth Defects at the University of Texas Southwestern Medical Center at Dallas. His lab studies muscle cells as a model for understanding how embryonic cells adopt specific fates and how programs of cell differentiation and morphogenesis are controlled during development. There are three major muscle cell types: cardiac, skeletal and smooth, which express distinct sets of genes controlled by different combinations of transcription factors and extracellular signals. They have focused on discovering novel transcription factors that control development of these muscle cell types and remodeling in response to cardiovascular and neuromuscular diseases. The processes involved in muscle development are evolutionarily ancient and conserved across diverse organisms. This conservation has enabled them to take a cross-species approach to dissect this problem by identifying myogenic regulatory genes in the fruit fly or in vertebrate embryos and to use these genes to perform gain and loss-of-function experiments in vivo and in vitro. Most recently, we have explored the roles of microRNAs in the control of muscle development and disease. Their long-term goal is to delineate the complete genetic pathways for the formation and function of each muscle cell type and to use this information to devise pharmacologic and genetic therapies for inherited and acquired muscle diseases in humans.Many former students and postdocs from our group are emerging as the next generation of leaders in cardiovascular medicine.

William K. Decker, PhD is an Assistant Professor in the Department of Pathology & Immunology at Baylor College of Medicine in Houston, Texas.  He received an undergraduate degree in Biology from Tufts University in Boston, Massachusetts and a PhD in Molecular and Human Genetics from Baylor College of Medicine. After further postdoctoral study at Baylor and a brief stint in industry, he returned to academia as a Senior Research Scientist in the Department of Stem Cell Transplantation and Cellular Therapy at the University of Texas MD Anderson Cancer Center, a position he held for seven years. His research has focused upon dendritic cell regulation of the Th-1 immune response, and his work has demonstrated that dendritic cells possess the ability to compare MHC class I and class II antigenic sequences via a novel regulatory complex involving tRNA molecules and their associated tRNA synthetases. He has also focused upon the soluble signaling mediators used by these so-called ''Th-1'' dendritic cells to mediate cellular immune responses. He is currently engaged in translating these basic discoveries into viable therapeutic regimens for the treatment of neoplastic disease.

Jay W. Schneider, M.D., Ph.D., Assistant Professor at UT Southwestern Medical School research interests include: stem cells, cardiomyocytes, chemical genetics/small molecules, neuronal and cancer stem cells and cell fate mechanisms.  His team is researching the molecular mechanism of cell fate in stem cells, with a focus on cell signaling, transcriptional regulatory and epigenetic pathways. They have recently identified a collection of structurally diverse and chemically interesting small molecules from a high throughput screen of the UTSW chemical library. These small molecules can instruct stem cells in fate decisions, providing an exciting new toolbox to explore mechanisms, and also providing the starting points for novel regenerative drug discovery. In addition to cardiac fate and developmental mechanisms, they have followed the chemical biology of these molecules into neuronal fate mechanisms and into the biology of the neural cancer stem cell. 

New Jersey


Wise Young, PhD, MD is the Richard H. Shindell Distinguished Chair in Neuroscience and Founding Director W.M. Keck Center for Collaborative Neuroscience at Rutgers University. The W. M. Keck Center for Collaborative Neuroscience studies brain and spinal cord injury using a wide variety of techniques to assess mechanisms and treatments of acute injury.  Their main research goals are to discover, test, and develop practical therapies for brain and spinal cord injury. These therapies are aimed at preventing progressive damage in the brain and spinal cord. optimizing the function of surviving axons remyelination and regeneration. They collaborate with many laboratories around the world in order to move therapies quickly from laboratory to clinical trial. Well-known as a leader in spinal cord injury research, Dr. Young has appeared on "20/20" with Barbara Walters and Christopher Reeve, "48 Hours," "Today," "Eye-to-Eye," Fox News and CNN's news magazine with Jeff Greenfield. His work has been featured in a Life magazine special edition, USA Today, and innumerable other news, talk and print presentations throughout the world and TIME Magazine named him "America's Best" in the field of spinal cord injury research. He is one of the world's most outstanding neuroscientists and a foremost leader in spinal cord injury research. His pioneering standardized rat spinal cord injury model is used worldwide for testing therapies. He was the founder and editor-in-chief of the Journal of Neurotrauma, organizer of National and International Neurotrauma Societies, member of the Advisory Committees for the NIH, the National Academy of Sciences, NICHD and many spinal cord injury organizations.  Dr. Young also serves as Chairman of the Advanced Therapeutics and Clinical Studies Committee.  We are honored to have the National Paralysis Foundation of Dallas's 1997 Tall Texan of the Year back in Austin in September. 



Lawrence S.B. Goldstein, Ph.D., Professor in the Department of Cellular & Molecular Medicine at the University of California, San Diego (UCSD) School of Medicine and Howard Hughes Medical Institute Investigator, is the Director of the UC San Diego Stem Cell Program. His research is focused on understanding the molecular mechanisms of movement inside brain cells and how failures in the movement systems may lead to neurodegenerative diseases. His laboratory has discovered important links between transport processes and diseases such as Alzheimer's and Huntington's diseases. Goldstein has had an active role in national science policy, having served on several public scientific advisory committees, in addition to serving as an expert commentator on the issue of stem cell research by print and broadcast media.  As a co-founder and consultant of the biotechnology company Cytokinetics, he has also had an active role in private industry where he has gained experience in translating scientific insights to new therapeutic approaches. Dr. Goldstein has served as a national leader in stem cell research and policy, including serving as co-chair of the scientific advisory committee for the campaign to pass California's Proposition 71, a voter-endorsed measure to provide $3 billion in stem cell research funding in California. Goldstein has also appeared on numerous occasions before the California legislature and the U.S. Congress and Senate to testify in support of stem cell research and biomedical research funding.

Dr. Jane S. Lebkowski, Ph.D.

has been Chief Scientific Officer and Senior Vice President of Geron Corporation since May 2011.  She has also served as Chief Scientific Officer of Cell Therapy and Senior Vice President of Cell Therapy.  Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases.  The company is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and recently initiated a Phase 1 clinical trial in spinal cord injury--- First in our nation to be federally approved for human embryonic stem cell based human clinical trials. Geron's lead therapeutic candidate (GNOPC1) contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with complete American Spinal Injury Association (ASIA) Impairment Scale grade Athoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.  The therapy could provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year. The FDA's clearance of this Geron trial marked the beginning of what is potentially a new chapter in medical therapeutics.

Roman Reed and his father Don Reed have worked tirelessly to inspire and renew California's Roman Reed Spinal Cord Injury Research Act (1999). As a result, $14 million in state funds has been awarded to scientists conducting research in spinal cord regeneration. An additional $64 million has been leveraged from outside sources. Both Don and Roman are founding members of the Stem Cell Action Coalition, which seeks to unite the pro-cures community in the US.

Roman Reed, paralyzed in a college football game in 1994.Roman joined the Stanford Partnership for Spinal Cord Injury Repair to promote research and awareness on behalf of all those with spinal cord injury and dysfunction. President Obama invited him and his parents to the March 9, 2009, ceremony commemorating the historic reversal of the government's ban on the use of federal funding for embryonic stem cell research. Roman Reed runs the nonprofit "Roman Reed Foundation" which funds valuable research providing hope for spinal cord injury.

Don Reed served on the Board of Directors for the Proposition 71 Initiative, which began California's $3 billion stem cell program.  He is currently Vice President for Public Policy for the Americans for Cures Foundation, as well as founder and co-chair for Californians for Cures.  Don work s to advance and protect stem cell research freedom and funding, working on numerous state,  national, and international efforts.  Author of five books and a frequent contributor to the Huffington Post, Don's motivation began with his son, Roman Reed, paralyzed in a college football game in 1994.



Dr. Shinn-Zong (John) Lin, M.D., Ph.D. is a Professor of Neurosurgery and Vice Superintendent of the Center of Neuropsychiatry at China Medical University Hospital in Taiwan. With an M.D. from National Defense Medical Center in Taipei, a Ph.D. in Physiology and Biophysics from State University of New York at Stony Brook and a Master's degree in Medical Management from Tulane University, he has served as a Professor of Neurosurgery at the National Defense Medical Center, Chairman of the Department of Neurosurgery at Tri-Service General Hospital, and a Professor of Neurosurgery and Chairman of NeuroMedical Scientific Center at Tzu-Chi General Hospital. He is the inventor of many patented treatment technologies for Brain Damage patients including the patentable technology entitled, "Treatment of Brain Damage using umbilical Cord Blood Cells". His background also includes: Membership of Editorial Boards Tzu-Chi Nursing Journal, Tzu-Chi Medical Journal, Formosan Journal of Surgery, Acta Neurologica Taiwanica, Surgical Neurology and Taiwan Neuroscience Alliance, Presidency of the International Neural Transplantation and Repair Meeting, Membership of 23 Professional Societies, 25 Distinguished Honors and Awards, 41 Research Programs, 3 Patents, 161 Publications in refereed journals, 25 Books and 178 Conference Papers and Invited Lectures. He is a highly accomplished neurosurgeon and applied neuroscientist for innovative therapies for stroke and neurodegenerative diseases. Dr. Lin is also a Member of the Advanced Therapeutics and Clinical Studies Committee.


Cesar V. Borlongan, PhD is Professor and Vice-Chairman for Research, Department of Neurosurgery and Brain Repair at the University of South Florida College of Medicine. Dr. Cesar Borlongan's laboratory embodies translational "bench to clinic" research in advancing cell therapy for stroke and other CNS diseases. Clinically relevant animal models of human neurological disorders used to test effectiveness and safety, as well as mechanisms of action of stem cells, which are pivotal parameters for clinical application.  The Center has a directed clinical focus to achieve significant enhancement for the care of citizens with Stroke, Parkinson's disease, and other movement disorders, Alzheimer's and Vascular dementia, genetically related neurological diseases, and other chronically disabling disorders associated with an aging population.

New York


Denis Rodgerson, Ph.D, Professor Emeritus Pathology and Laboratory Medicine at UCLA, is the Director of Stem Cell Science at NeoStem, Inc. a company that specializes in the collection, processing and long term storage of adult stem cells for the future therapeutic use in the treatment of heart disease, diabetes, autoimmune disorders, cancer and other critical health problems. Dr. Rodgerson was the initial founder of NeoStem, and now has responsibility for the company's stem cell science programs.   He has been a consultant to many institutions and corporations, including NASA and the National Bureau of Standards, is the inventor on several patents and has published more than 150 articles in the medical and scientific literature.



Ratan Bhardwaj, M.D., Ph.D. is a Pediatric Neurosurgeon at Barrow Neurological Institute at Phoenix Children's Hospital in Arizona. Dr. Bhardwaj completed his Pediatric Neurosurgery fellowship in 2011 and worked with Dr. Mike Levy and Hal Meltzer. He is a graduate the University of Toronto Neurosurgical Residency Training Program and is versed in all aspects of clinical neurosurgical care. His research interest lies in the area of neural stem cells. 

Special Announcements  

Texans for Stem Cell Research

6th Annual Singin' for Cures Fundraiser 

September 30th, 2011

6:30 PM - 10:30 PM

Historic Saengerrunde (next to Scholz Garten) 

1607 San Jacinto Boulevard




RSVP and for information about the Special Guests:  

Official Event Site

Contact David to reserve tables

Most days we honor celebrate the past.   

This one celebrates the future.


World Stem Cell Awareness Day 

October 5th, 2011  


Stem Cell Awareness Day brings together the organizations and individuals around the world who are working every day to ensure that we realize the benefits of what is one of the most promising fields of science in our time. This year, Texans for Stem Cell Research will join stem cell groups around the world to celebrate Stem Cell Awareness Day and we are actively getting the local communities across Texas involved. For the millions of people around the world who suffer from incurable diseases and injury, Stem Cell Awareness Day is a day to celebrate the scientific advances made to-date and be hopeful of what is yet to come.  Beyond treating disease, stem cell research also holds promise for developing powerful environmental toxicity tests, drug screening, and diagnostics. Stem cell therapies also offer an opportunity to restore quality of life for patients and their families, while saving billions of dollars we spend on lost productivity and medical care.  How can you get involved with World Stem Cell Awareness Day in Texas?


Stand up for Stem Cells and Give 5%


Texans for Stem Cell Research will proudly unite the local communities 

across Texas for a day of celebration and hope.


Your business can support this day of awareness and "Stand up for Stem Cells" by Giving 5%  in Texas on Wednesday, October 5th. Visit our official website to Stand up For Stem Cells on World Stem Cell Awareness Day to learn more about the public lectures and events in your area go to txstemcell.org  Contact us by September 25, 2011 for materials and to be included on the posters that will be displayed aross Texas. Contact David at 



The world as we know it is about to change.


Thank You to Our Recent Sponsors

2011 Learn for Life Education Series Presenting Sponsor:  






Recent initiatives by several national organizations such as the National Marrow Donor Program and the  American Academy of Pediatrics have begun educating parents about cord blood banking.  StemCyte is a global company, headquartered in California, which collects Cord Blood donations.  Stemcyte is a Participating Member of the National Marrow Donor Program (NMDP) Cord Blood bank network. They are the most active bank in the NMDP public network.  StemCyte is accredited under the international FACT/Netcord standards and FDA registered, ASHI accredited, CLIA accredited, CA Biologics licensed.  


*Cord Blood Banks by Location   

Banks with medical need programs 

Your Guide to Healthy Cord Blood 








2011 Learn for Life
Donors and Loyal Supporters 








Texans for Stem Cell Research (TSCR) is a non-partisan, non-profit 501(c)3, volunteer organization dedicated to the advancement of stem cell clinical applications. We promote FDA approved clinical trials that have the potential for new novel clinical therapy approaches for treating the millions suffering from debilitating disease and injury. TSCR hosts education events and provides advocacy support to industry leaders, partner organizations, researchers and doctors conducting stem cell research in Texas.  TSCR assists the Texas based research teams and institutions by fostering strategic funding collaborations with potential partners.  Stem cell therapies are advancing with promising results in clinical trials and TSCR will continue to promote safe, ethical and responsible research to accelerate translational efforts in Texas.    

3112 Windsor Suite 106,  Austin, Texas 78703


You can help our organization continue to provide important education about promising stem cell research through your donations.  Your contributions provide support for our educational programs and advocacy efforts. We must keep our community informed about the importance of this research and it's potential to provide treatments and cures for diseases and debilitating injuries. You can make a gift through our secure website donation page, cause page or by check.  We thank you in advance for your support and hope you will join our growing organization in 2011.   

   Cause Page Find us on Facebook            

Contact David Bales for additional opportunities